Russell Investments Group Ltd. Sells 63,845 Shares of Omnicell, Inc. (NASDAQ:OMCL)

Russell Investments Group Ltd. reduced its stake in shares of Omnicell, Inc. (NASDAQ:OMCL – Get Rating) by 67.3% in the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 31,028 shares of the company’s stock after selling 63,845 shares during the period. Russell Investments Group Ltd.’s holdings in Omnicell were worth $1,564,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. UMB Bank n.a. grew its holdings in shares of Omnicell by 29.0% in the fourth quarter. UMB Bank n.a. now owns 930 shares of the company’s stock valued at $47,000 after acquiring an additional 209 shares in the last quarter. Fifth Third Bancorp grew its holdings in shares of Omnicell by 48.9% in the fourth quarter. Fifth Third Bancorp now owns 989 shares of the company’s stock valued at $50,000 after acquiring an additional 325 shares in the last quarter. Parallel Advisors LLC grew its holdings in shares of Omnicell by 124.3% in the fourth quarter. Parallel Advisors LLC now owns 1,032 shares of the company’s stock valued at $52,000 after acquiring an additional 572 shares in the last quarter. CWM LLC grew its holdings in shares of Omnicell by 166.0% in the fourth quarter. CWM LLC now owns 1,540 shares of the company’s stock valued at $78,000 after acquiring an additional 961 shares in the last quarter. Finally, Covestor Ltd grew its holdings in shares of Omnicell by 424.2% in the first quarter. Covestor Ltd now owns 844 shares of the company’s stock valued at $109,000 after acquiring an additional 683 shares in the last quarter.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on OMCL shares. TheStreet lowered Omnicell from a “c” rating to a “d+” rating in a report on Tuesday, February 28th. SVB Leerink reaffirmed a “market perform” rating on shares of Omnicell in a report on Friday, January 27th. StockNews.com began coverage on Omnicell in a research note on Thursday, May 18th. They issued a “hold” rating on the stock. Piper Sandler upped their price objective on Omnicell from $55.00 to $66.00 and gave the company an “overweight” rating in a research note on Friday, January 27th. Finally, KeyCorp upped their price objective on Omnicell from $65.00 to $70.00 in a research note on Wednesday, May 3rd. Three investment analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $72.22.

Insiders Place Their Bets

In other Omnicell news, Director Joanne B. Bauer sold 13,115 shares of the stock in a transaction on Tuesday, March 7th. The stock was sold at an average price of $54.24, for a total transaction of $711,357.60. Following the sale, the director now owns 28,096 shares in the company, valued at $1,523,927.04. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Company insiders own 2.61% of the company’s stock.

Omnicell Trading Down 3.5 %

NASDAQ:OMCL opened at $72.02 on Wednesday. The company has a market cap of $3.25 billion, a P/E ratio of -180.05, a P/E/G ratio of 10.62 and a beta of 0.90. The stock’s fifty day moving average price is $61.69 and its two-hundred day moving average price is $55.81. Omnicell, Inc. has a 1 year low of $46.11 and a 1 year high of $125.17. The company has a debt-to-equity ratio of 0.50, a current ratio of 2.06 and a quick ratio of 1.75.

Omnicell (NASDAQ:OMCL – Get Rating) last posted its earnings results on Tuesday, February 28th. The company reported $0.02 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.18) by $0.20. The firm had revenue of $297.67 million for the quarter, compared to the consensus estimate of $286.32 million. Omnicell had a positive return on equity of 5.38% and a negative net margin of 1.39%. As a group, analysts expect that Omnicell, Inc. will post 0.5 EPS for the current year.

Omnicell Company Profile

(Get Rating)

Omnicell, Inc engages in the provision of medication management automation solutions and adherence tools for healthcare systems and pharmacies. Its solutions include intelligence, platform and interoperability, central pharmacy dispensing, medication adherence, population health and point of care automation.